Recombinant DNA Fermenter, circa 1977

Fermenters like this one used genetically-manipulated bacteria to produce the first human insulin in 1977 and the first human growth factor in 1979. Credit: © SSPL / Science Museum" />Fermenters like this one used genetically-manipulated bacteria to produce the first human insulin in 1977 and the first human growth factor in 1979. Credit: © SSPL / Science Museum In 1972, Uni

Written byTia Ghose
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In 1972, University of California, San Francisco, biochemist Herbert Boyer met Stanford University geneticist Stanley Norman Cohen at a meeting in Hawaii. The two then kicked off a collaboration that eventually led to the creation of the first recombinant DNA, a landmark that ushered in the era of modern biotechnology. By combining Cohen's expertise with bacterial plasmids and Boyer's know-how about restriction enzymes, the two found that they could use bacteria as tiny factories for producing many human proteins. Boyer went on to found Genentech in 1976.

In order to produce the proteins in mass quantities, the fledgling biotech company needed a way to grow transgenic bacteria on an industrial scale. To do that, they turned to the ancient art of fermentation. People had made wine, bread, and beer for thousands of years, yet it wasn't until World War I when tons of acetone and other explosive ingredients were needed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies